Subsequently, mutations in both IDH1 and IDH2 were found in more than 70% of gliomas and secondary glioblastomas (discussed above) [81,117], as well as in AML, with a frequency of approximately 15% [118]. Here, IDH2 is linked to central nervous system cancer.